Company: ZLAB
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001628280-25-008409
Chunk: 20

Company: Zai Lab Ltd
Filing Date: 2025-02-27
Form: 10-K
Item: Item 16
Chunk 20
---
 current liabilities1358,720 82,972 Total current liabilities299,385 203,067 Deferred income31,433 28,738 Non-current operating lease liabilities813,712 8,047 Other non-current liabilities325 325 Total liabilities344,855 240,177 Commitments and contingencies (Note 20)Shareholders’ equityOrdinary shares (par value of $0.000006 per share; 5,000,000,000 shares authorized, 1,082,614,740 and 977,151,270 shares issued as of December 31, 2024 and 2023, respectively; 1,077,702,540 and 972,239,070 shares outstanding as of December 31, 2024 and 2023)7 6 Additional paid-in capital3,264,295 2,975,302 Accumulated deficit(2,453,083)(2,195,980)Accumulated other comprehensive income 50,515 37,626 Treasury stock (at cost, 4,912,200 shares as of both December 31, 2024 and 2023)(20,836)(20,836)Total shareholders’ equity840,898 796,118 Total liabilities and shareholders’ equity1,185,753 1,036,295 

The accompanying notes are an integral part of these consolidated financial statements. 

F-5

Zai Lab Limited

Consolidated Statements of Operations

(in thousands of $, except for number of shares and per share data)

Year Ended December 31,Notes202420232022RevenuesProduct revenue, net10397,614 266,719 212,672 Collaboration revenue1,374 — 2,368 Total revenues398,988 266,719 215,040 ExpensesCost of product revenue(147,118)(95,816)(74,018)Cost of collaboration revenue(742)— — Research and development(234,504)(265,868)(286,408)Selling, general and administrative(298,741)(281,608)(258,971)Gain on sale of intellectual property— 10,000 — Loss from operations(282,117)(366,573)(404,357)Interest income37,105 39,797 14,582 Interest expenses(2,254)— — Foreign currency losses(